Naltrexone and buprenorphine combination in the treatment of opioid dependence. - Wikidata - awgldk - TriplyDB

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

http://www.wikidata.org/entity/Q44351532

about

Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction Endogenous opiates and behavior: 2006 Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A From research to the real world: buprenorphine in the decade of the Clinical Trials Network Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.Opioid dependence treatment: options in pharmacotherapy.The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.Management of relapse in naltrexone maintenance for heroin dependence.Advances in opioid antagonist treatment for opioid addiction.Evaluation of opioid modulation in major depressive disorder Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.The kappa opioid receptor: from addiction to depression, and back.Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor.Pharmacological enhancement of naltrexone treatment for opioid dependence: a review Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.Agonist-antagonist combinations in opioid dependence: a translational approach Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Development of κ opioid receptor antagonists.The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208 Long-acting injectable naltrexone for the treatment of alcohol dependence.Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy.Heroin anticraving medications: a systematic review.Treatment outcome for flexible dosing buprenorphine maintenance treatment.Effect of buprenorphine dose on treatment outcome.Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.Antagonist-agonist combinations as therapies for heroin addiction: back to the future?Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Favorable mortality profile of naltrexone implants for opiate addiction.A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone.Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction.

P2860

Q26770785-D811F92C-38AD-4A74-89CB-4B6F60A112AE Q28752585-8165C09D-94C6-4FD4-89F5-8FF5C132231E Q30467220-AF656D04-ED79-43F5-BE96-D5066823ED5E Q33783274-D0A1E85F-04DC-43C8-BFB9-3FA9135CD261 Q33842725-7EBB062D-AC10-49F1-B21A-07A333872CC4 Q33868638-B8AA0DAB-FA2D-438E-9923-6395A60C025D Q33890721-34A9866E-9DEF-44CC-9133-BB064FC62015 Q34073200-E7B5D9E5-C41F-434B-A11E-FB23206A1F59 Q34128519-1DB7F5B7-0EA2-47BE-8B1A-28AF0F8A2E52 Q34262649-3D7A039A-3A7C-4310-9237-CB3FC87D2C02 Q34454397-4E5CAAF2-2A7A-418F-8F9D-0CD1BB16644C Q34517116-EE23C440-5C60-453C-B688-AD1360DB2EDF Q34650892-50FB2E83-0E80-4E8A-9E86-06A18DEB4355 Q35067118-BD229D86-1AFF-46EC-9BBF-65C4840C7F95 Q35084340-249A2110-665C-4144-A3CA-1722CAF27285 Q35090939-1CD14654-91D6-4678-9A54-1DBD067276E1 Q35669185-7A685B51-1E66-4E7D-81A8-713774E3A32B Q35848930-9E437767-7CCC-47B4-9640-C601B50A4EBB Q36104010-0956C53C-BE93-4D12-B450-457D66D56E70 Q36110480-56C81FD8-D08D-439C-B77C-3765E2F2DCDB Q36251877-A89192CC-297C-4959-A418-796AECDBD4E3 Q36394429-5CBD9484-4EE9-4C12-9C1A-6C7A646E22D6 Q36728154-4A26B53A-7D5A-4E67-A86D-9320BED2875E Q36836438-06D19AE7-2601-4E3F-8613-BA14AFA2886C Q36887197-2A2EDCCC-88FF-4FA1-B940-BB370BDC5580 Q36972683-06104005-DC10-4667-A1F5-434702CAC679 Q37140536-5F842A5F-CDC5-4996-88DD-88B1E82D1D40 Q37483673-D12189C4-066D-4772-B3C3-986AE1B30AE7 Q37613483-3106F3A0-C579-42CE-B585-A6FDFCC2F615 Q37800930-E8827F8E-547E-4769-8BC8-C79EF905BA9B Q37969169-66C8FB27-DE17-44E9-9AC8-514081E93BDF Q37987271-95848177-50B3-4575-8B74-FFD90E3E35F7 Q38716082-179AAA79-F6B3-4E83-BC33-70F236AEB19B Q39902056-529ED882-4521-4008-ACB0-3CF85953AEB4 Q41537125-88367F75-AED4-4070-9CEE-5EEB2C7F5184 Q41639865-5D7E7D84-42E8-42BB-8E9B-27909C52A15D Q43100374-23970347-1D74-4D84-8B51-FF70F446A650 Q47282815-58CDDC11-4B98-4A55-86F6-14C1CB791DCD Q47753097-550A7ECC-3E0A-4908-A061-515A9F0B2C9F Q47988659-14263154-4C7D-4300-A685-1A9B464982A3

P2860

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

http://www.wikidata.org/entity/Q44351532

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@en

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@nl

type

label

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@en

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@nl

prefLabel

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@en

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@nl

P1433

Q44351532-E06C9BF1-DF58-4822-8983-E2DFC872F671

P1476

Q44351532-27D3B598-2406-42A3-9DF4-8E6C1B06B69E

P2093

Q44351532-4456A276-937E-4CF7-9400-88BE268CD879

Q44351532-7FACD873-B85D-4633-A072-FEA5905104C4

Q44351532-9906D116-9249-4B4A-A5F5-B409E672346E

P2860

Q44351532-02305C2F-9B7E-4D0F-A288-9E05057D2885

Q44351532-177E5923-6CC7-4F66-9A9A-16AECCD260A8

Q44351532-1B00D2C9-D0E5-473D-A567-CFD51CAC283F

Q44351532-1C950176-7FF1-45A6-AA86-03225747B859

Q44351532-1E5D1240-F89D-4B33-9CC4-59DBF5B87D0F

Q44351532-21917553-800E-4FCE-A72F-7D91D697C447

Q44351532-31B917DB-D573-4F0D-8A39-662864A026FE

Q44351532-3362D884-7E55-4EEE-AA53-25B6FDEAA12E

Q44351532-4157FC77-7B09-47D6-88F7-DBDFF736B1B1

Q44351532-5BD5DB1B-4415-4B4B-90AF-09491E910C7F

P304

Q44351532-62221458-03A5-4271-B4CF-13DAA3D6F060

P31

Q44351532-73DB60AE-84A0-4CC4-8EBE-9D17ED6A1AFD

P356

Q44351532-7C46E6CD-ED3F-451D-A0D9-FDBB33BBF1D3

P407

Q44351532-C4B749C3-2F44-4388-BA50-1016C90A3BA4

P433

Q44351532-CA68568F-6418-425F-9EA6-3E9BF96D04C8

P478

Q44351532-38F4B24C-4F85-4D8A-A627-D88E0A2A5887

P577

Q44351532-810F8C4F-71F0-494C-BD59-55FF64FCF86D

P5875

Q44351532-F0B84428-E88B-41A6-97B6-DA75039B77C7

P698

Q44351532-B5E17B44-145E-46BF-9A61-F15A9A1E32FB

P921

Q44351532-86D738DB-85B5-4A1F-B3E1-B34E9F6E2345

Q44351532-c234eb9c-de9e-4055-85ce-c6100c71bc52

P356

0269881106060835

P1433

Journal of Psychopharmacology

P1476

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

@en

P2093

Fantoma A

http://www.w3.org/2001/XMLSchema#string

Gerra G

http://www.w3.org/2001/XMLSchema#string

Zaimovic A

http://www.w3.org/2001/XMLSchema#string

P2860

Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Buprenorphine treatment of refractory depression.

Depressive symptoms during buprenorphine treatment of opioid abusers.

A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence.

Pharmacologic treatments for heroin and cocaine dependence.

A review of the role of anti-opioid peptides in morphine tolerance and dependence.

Neural mechanisms of drug reinforcement.

Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway

Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence

P304

806-814

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0269881106060835

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7369574

http://www.w3.org/2001/XMLSchema#string

P698

16401652

http://www.w3.org/2001/XMLSchema#string

P921